Pacific Journal of Oncology & Immunotherapy
https://scienceget.org/index.php/pjoi
Vol. 1, No. 1, 2024
eISSN: 3067-8110
EDITORIAL
DOI: https://doi.org/10.70818/pjoi.2024.v01i01.027

Revolutionizing Cancer Treatment: Breakthroughs in Immune Checkpoint Inhibition and CAR-T Cell Therapy

Aung Naing*, *FACP*
* *Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA*

Cancer remains one of the leading causes of death worldwide, despite decades of research and innovation in cancer treatment. Traditional approaches such as surgery, chemotherapy, and radiation therapy have made significant strides in managing various forms of cancer, yet many cancers remain resistant to these treatments. In recent years, two revolutionary therapies have emerged: immune checkpoint inhibition and Chimeric Antigen Receptor T-cell (CAR-T) cell therapy. Both approaches aim to harness the body's immune system to target and eliminate cancer cells more effectively, offering hope to patients with cancers that were once considered incurable. This editorial explores the advancements in immune checkpoint inhibition and CAR-T cell therapy, their mechanisms, clinical applications, and the challenges that remain in their widespread adoption.

Keywords: CAR-T Cell Therapy, Cancer Immunotherapy, Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)

∗**Corresponding author**: Aung Naing

Received: September 05, 2024| **Accepted:** November 12, 2024| **Published:** December 31, 2024

Immune checkpoint inhibitors are a class of drugs that work by blocking the immune system's natural checkpoints, which are mechanisms that normally prevent the immune system from attacking normal cells in the body. By inhibiting these checkpoints, immune checkpoint inhibitors effectively release the "brakes" on the immune system, allowing it to target and destroy cancer cells. One of the most well-known immune checkpoint inhibitors is the drug pembrolizumab (Keytruda), which targets the programmed cell death protein 1 (PD-1) receptor. PD-1 is a checkpoint protein on immune cells that, when activated, dampens immune responses, preventing the immune system from attacking cancer cells. By inhibiting PD-1, pembrolizumab reactivates the immune response against tumors, leading to the destruction of cancer cells. Another checkpoint protein, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), is targeted by ipilimumab (Yervoy), which also enhances the immune system's ability to fight cancer. The development of immune checkpoint inhibitors has ushered in a new era of cancer immunotherapy, particularly in the treatment of cancers such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma. Clinical trials have shown that immune checkpoint inhibitors can lead to long-lasting remissions in patients with previously untreated cancers, with some patients experiencing complete responses. For instance, the combination of pembrolizumab and chemotherapy has shown promising results in treating metastatic non-small cell lung cancer (NSCLC), providing patients with improved survival rates compared to traditional chemotherapy alone [1]. Despite these successes, immune checkpoint inhibitors are not without limitations. While they are highly effective for some patients, many others do not respond to treatment. In

addition, the potential for immune-related adverse events (irAEs), such as autoimmune disorders, is a significant challenge. These side effects occur when the immune system attacks normal tissues in the body, leading to inflammation and damage to healthy organs. Managing these side effects requires careful monitoring and, in some cases, immunosuppressive therapy. Moreover, resistance to immune checkpoint inhibitors remains a significant hurdle. Tumors can develop mechanisms to evade immune detection, such as altering the expression of checkpoint proteins or creating an immunosuppressive tumor microenvironment. As a result, researchers are exploring combination therapies, such as combining immune checkpoint inhibitors with other immunotherapies, targeted therapies, or chemotherapy, to overcome these resistance mechanisms and enhance the effectiveness of treatment [2-4].

CAR-T cell therapy is another groundbreaking advancement in cancer treatment. Unlike immune checkpoint inhibitors, which work by enhancing the immune system's ability to recognize and attack cancer cells, CAR-T cell therapy involves genetically modifying a patient's T-cells to target and destroy cancer cells directly. This approach has shown remarkable success in treating certain blood cancers, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The process of CAR-T cell therapy begins by extracting T-cells from a patient's blood. These cells are then genetically engineered in the laboratory to express a chimeric antigen receptor (CAR), which allows them to recognize a specific antigen on the surface of cancer cells. Once the CAR-T cells are infused back into the patient, they are able to seek out and destroy cancer cells expressing the targeted antigen. The most well-known CAR-T cell therapies target the CD19 antigen, which is found on the surface of B-cells, making them effective for treating B-cell malignancies like ALL and NHL. The success of CAR-T cell therapy has been groundbreaking, with patients who had exhausted all other treatment options achieving durable remissions. For example, in clinical trials, Kymriah (tisagenlecleucel), a CAR-T cell therapy targeting CD19, has shown an overall remission rate of around 80% in pediatric and young adult patients with relapsed or refractory B-cell ALL [5, 6]. Another CAR-T cell therapy, Yescarta (axicabtagene ciloleucel), has demonstrated impressive efficacy in patients with relapsed or refractory large B-cell lymphoma, with an overall response rate of approximately 82% [7]. However, CAR-T cell therapy is not without its challenges. One of the most significant issues is the development of severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity. CRS occurs when the infused CAR-T cells activate a massive immune response, leading to a dangerous rise in cytokines that can cause fever, hypotension, and organ failure. Neurotoxicity, characterized by confusion, seizures, and encephalopathy, is another potentially life-threatening complication. These side effects can be managed with supportive care and immunosuppressive drugs, but they remain a barrier to the widespread use of CAR-T cell therapy, particularly in solid tumors [8, 9]. Additionally, the high cost of CAR-T cell therapy remains a significant concern. The process of manufacturing CAR-T cells is complex and time-consuming, leading to substantial costs for patients and healthcare systems. Efforts are underway to reduce the cost of CAR-T therapy by streamlining the manufacturing process and exploring alternative methods for cell modification.

Both immune checkpoint inhibition and CAR-T cell therapy have shown promise in treating cancer, but resistance to treatment remains a major obstacle. Researchers are exploring combination therapies as a potential solution to this problem. By combining immune checkpoint inhibitors with CAR-T cell therapy, for example, it may be possible to enhance the effectiveness of both treatments and overcome resistance mechanisms. One promising combination strategy is the use of immune checkpoint inhibitors to enhance the efficacy of CAR-T cell therapy. Studies have shown that checkpoint inhibition can improve the persistence and functionality of CAR-T cells, allowing them to better recognize and eliminate cancer cells. For instance, combining pembrolizumab with CAR-T cell therapy has shown promising preclinical results in enhancing CAR-T cell expansion and improving anti-tumor responses [10]. Clinical trials are now underway to test this combination approach in patients with various types of cancer. Similarly, combining CAR-T cell therapy with other targeted therapies, such as monoclonal antibodies or small molecule inhibitors, could help overcome resistance and improve patient outcomes. By targeting multiple pathways simultaneously, these combination therapies may increase the likelihood of achieving durable remissions and reduce the risk of relapse.

The field of cancer immunotherapy is rapidly evolving, with immune checkpoint inhibition and CAR-T cell therapy leading the way. Both therapies have shown impressive results in clinical trials, offering hope for patients with cancers that were once considered incurable. However, significant challenges remain, including the management of side effects, resistance to treatment, and the high cost of therapy. Looking forward, the future of cancer immunotherapy lies in improving the safety and efficacy of existing therapies, as well as expanding their applications to a wider range of cancers. Researchers are working on developing next-generation CAR-T cells that can target solid tumors, which have historically been more challenging to treat with CAR-T cell therapy. Additionally, new immune checkpoint inhibitors targeting different checkpoints, such as TIGIT and LAG-3, are being developed to further enhance the immune system's ability to fight cancer [11-13]. Combination therapies hold great promise for overcoming resistance and improving patient outcomes. By combining immune checkpoint inhibitors, CAR-T cell therapy, and other targeted therapies, it may be possible to create a multi-pronged approach to cancer treatment that offers long-lasting and durable remissions.

In conclusion, immune checkpoint inhibition and CAR-T cell therapy represent two of the most significant advancements in cancer treatment in recent years. While both therapies have shown remarkable success in treating certain cancers, ongoing research and clinical trials will be crucial to overcoming the remaining challenges and expanding their applications to a broader range of cancer types.

REFERENCES

1. Brahmer JR, Paz-Ares L. Pembrolizumab versus chemotherapy in advanced non–small-cell lung cancer. N Engl J Med. 2020;372(21):2028-2040.
2. Garon EB, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
3. Robert C, et al. Ipilimumab plus nivolumab versus ipilimumab alone in advanced melanoma. N Engl J Med. 2015;372(21):2113-2123.
4. Parvez MH, Moula SG, Islam MM, Badruddoza AS, Ali MI. Impact of Surgeon Experience on Outcomes in Prostate Cancer Surgery; A Study of Learning Curves and Best Practices. Asia Pacific Journal of Cancer Research. 2024 Dec 31;1(1):23-31.
5. Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
6. Locke FL, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2019;380(8):720-731.
7. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy – Assessment and future directions. N Engl J Med. 2017;377(25):2520-2527.
8. Islam MS, Abdullah KS, Sadat CM, Islam MI. Surgical Innovations and Outcomes in the Management of Rectal Cancer: A Departmental Study on Advanced Techniques and Postoperative Care. Asia Pacific Journal of Cancer Research. 2024 Dec 31;1(1):14-22.
9. Teachey DT, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Blood. 2016;128(1):53-58.
10. Kambhampati S, et al. Combining checkpoint inhibitors with CAR T-cell therapy: A promising strategy to enhance therapeutic efficacy. J Clin Oncol. 2021;39(12):1380-1391.
11. Liao W, et al. Targeting LAG-3 in cancer immunotherapy. J Immunother Cancer. 2020;8(1):1-7.
12. Sakuishi K, et al. Targeting TIGIT to enhance cancer immunotherapy. Cell Rep. 2021;34(7):108798.
13. Gupta R, Rahman MT. Revolutionizing Cancer Care; Breakthroughs in Therapeutics and Diagnostics for Precision Oncology. Asia Pacific Journal of Cancer Research. 2024 Dec 31;1(1):1-3.